Earnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00 [Yahoo! Finance]
Marinus Pharmaceuticals, Inc. (MRNS)
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.marinuspharma.com/investor-relations
Company Research
Source: Yahoo! Finance
The numbers were weak, with revenues of US$7.7m coming in 16% short of analyst estimates. Statutory losses were US$0.68 per share, 3.0% larger than what the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. Check out our latest analysis for Marinus Pharmaceuticals Following the latest results, Marinus Pharmaceuticals' eleven analysts are now forecasting revenues of US$39.4m in 2024. This would be a substantial 39% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 25% to US$1.98. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$41.1m and losses of US$2.23 per share
Show less
Read more
Impact Snapshot
Event Time:
MRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNS alerts
High impacting Marinus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MRNS
News
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at Truist Financial Co. from a "strong-buy" rating to a "hold" rating.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "hold" rating re-affirmed by analysts at TD Cowen.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Royal Bank of Canada from $3.00 to $1.00. They now have a "sector perform" rating on the stock.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Cantor Fitzgerald from $13.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
MRNS
Earnings
- 8/13/24 - Miss
MRNS
Sec Filings
- 10/31/24 - Form SCHEDULE
- 10/24/24 - Form 8-K
- 10/15/24 - Form 4
- MRNS's page on the SEC website